O Neil Global Advisors Inc. Has $467,000 Position in iRhythm Technologies $IRTC

O Neil Global Advisors Inc. lessened its stake in iRhythm Technologies (NASDAQ:IRTC) by 70.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,718 shares of the company’s stock after selling 6,458 shares during the quarter. O Neil Global Advisors Inc.’s holdings in iRhythm Technologies were worth $467,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IRTC. Hillsdale Investment Management Inc. boosted its stake in shares of iRhythm Technologies by 2.0% during the 3rd quarter. Hillsdale Investment Management Inc. now owns 38,250 shares of the company’s stock valued at $6,579,000 after buying an additional 750 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of iRhythm Technologies during the third quarter worth $275,000. Synovus Financial Corp boosted its position in iRhythm Technologies by 2.4% during the third quarter. Synovus Financial Corp now owns 8,029 shares of the company’s stock valued at $1,381,000 after purchasing an additional 191 shares during the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new stake in iRhythm Technologies during the third quarter valued at $101,000. Finally, M&G PLC grew its stake in iRhythm Technologies by 3.3% in the third quarter. M&G PLC now owns 76,868 shares of the company’s stock valued at $13,221,000 after purchasing an additional 2,470 shares in the last quarter.

Analyst Ratings Changes

A number of research firms have recently weighed in on IRTC. Freedom Capital raised iRhythm Technologies to a “strong-buy” rating in a research note on Thursday, January 15th. Wells Fargo & Company dropped their price objective on iRhythm Technologies from $225.00 to $200.00 and set an “overweight” rating on the stock in a report on Friday. Wall Street Zen upgraded shares of iRhythm Technologies from a “hold” rating to a “buy” rating in a research note on Saturday. The Goldman Sachs Group boosted their target price on shares of iRhythm Technologies from $180.00 to $202.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Finally, JPMorgan Chase & Co. cut their price target on shares of iRhythm Technologies from $240.00 to $215.00 and set an “overweight” rating on the stock in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $211.62.

Insider Activity

In other iRhythm Technologies news, insider Chad Patterson sold 280 shares of iRhythm Technologies stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total value of $51,752.40. Following the transaction, the insider directly owned 43,387 shares of the company’s stock, valued at $8,019,219.21. The trade was a 0.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Patrick Michael Murphy sold 2,478 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total value of $458,008.74. Following the transaction, the insider owned 53,281 shares of the company’s stock, valued at approximately $9,847,927.23. This trade represents a 4.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.68% of the stock is currently owned by insiders.

Key Headlines Impacting iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q4 results beat estimates — Revenue $208.9M (+27.1% YoY) and EPS $0.29 topped consensus; management reported record quarterly revenue, improved gross margin and positive GAAP net income for the quarter. Globe Newswire: Q4 Results
• Positive Sentiment: Beating the street — Third‑party coverage highlights the earnings and revenue beat and improved profitability metrics (adjusted EBITDA, cash flow). These operational improvements support upside case over time. Zacks: Earnings Beat
• Neutral Sentiment: Company materials available — Earnings call transcript and slide deck published for investors to evaluate management commentary and forward drivers (AC C presentations and upcoming data cadence). Useful for confirming guidance/assumptions. Seeking Alpha: Call Transcript
• Neutral Sentiment: Market coverage noted positive market reaction after the print in some outlets — short-term sentiment can swing quickly as investors parse details. MassDevice: Market Reaction
• Negative Sentiment: Analysts trimmed price targets across several firms today (Canaccord, JPMorgan, Wells Fargo, Robert W. Baird) — ratings remain generally positive/overweight but lower targets reduce near‑term upside expectations and can pressure the stock. Benzinga: Analyst Target Changes
• Negative Sentiment: Insider selling and institutional rebalancing highlighted — multiple insider sales and large shifts in fund holdings raise concern about near-term selling pressure and supply overhang. Quiver: Insider & Institutional Activity

iRhythm Technologies Trading Down 5.0%

NASDAQ:IRTC opened at $150.96 on Monday. The company’s 50 day moving average is $164.65 and its 200-day moving average is $171.48. The company has a quick ratio of 4.48, a current ratio of 4.63 and a debt-to-equity ratio of 4.25. iRhythm Technologies has a 12 month low of $92.52 and a 12 month high of $212.00. The firm has a market cap of $4.88 billion, a price-to-earnings ratio of -107.83 and a beta of 1.06.

iRhythm Technologies (NASDAQ:IRTC) last posted its earnings results on Thursday, February 19th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.27. The business had revenue of $208.89 million for the quarter, compared to analyst estimates of $202.61 million. iRhythm Technologies had a negative net margin of 5.96% and a negative return on equity of 28.15%. iRhythm Technologies’s revenue was up 27.1% compared to the same quarter last year. During the same period last year, the business posted ($0.04) EPS. Equities analysts anticipate that iRhythm Technologies will post -1.98 EPS for the current year.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.